Skip to main content
Top
Published in: Tumor Biology 8/2014

01-08-2014 | Research Article

Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution

Authors: Wei-gen Zeng, Zhi-xiang Zhou, Jian-wei Liang, Hui-rong Hou, Zheng Wang, Hai-tao Zhou, Xing-mao Zhang, Jun-jie Hu

Published in: Tumor Biology | Issue 8/2014

Login to get access

Abstract

Desmoid tumors are rare soft tissue tumors with limited data on their management and prognosis. We sought to determine the rates of recurrence after surgery for desmoid tumors and analyze factors predictive of recurrence-free survival (RFS). From February 1976 to October 2011, 233 consecutive patients with desmoid tumors who underwent macroscopically complete resection were included in this study. Clinicopathologic and treatment characteristics were evaluated to determine predictors of recurrence. Patterns of presentation included primary (n = 156, 67.0 %) and locally recurrent (n = 77, 33.0 %) disease initially treated elsewhere. Most patients had a R0 resection (n = 169, 72.5 %). In addition to surgery, 43 (18.5 %) patients received radiotherapy and 10 (4.3 %) patients received systemic therapy. Median follow-up was 54 months; recurrence disease was observed in 62 (26.6 %) patients. The estimated 5- and 10-year RFS was 74.2 % (95 % confidence interval (CI), 68.3–80.1) and 70.7 % (95 % CI, 64.2–77.2), respectively. Factors associated with worse RFS were tumor size larger than 5 cm (hazard ratio (HR) = 3.757; 95 % CI, 1.945–7.259; p < 0.001), extra-abdominal tumor location (abdominal wall referent; HR = 3.373; 95 % CI, 1.425–7.984; p = 0.006), and R1 resection status (HR = 1.901; 95 % CI, 1.140–3.171; p = 0.014). Patients were grouped according to the number of unfavorable prognostic factors; the 10-year RFS rates of patients with zero, one, two, and three prognostic factors were 100, 86.9, 48.5, and 34.4 %, respectively (p < 0.001). Regardless of primary or recurrent disease, surgical resection remains central to the management of patients with desmoid tumors. However, there are clearly different prognostic subgroups that could benefit from different therapeutic strategies, and a wait-and-see policy is a possible option for a subset of patients.
Literature
1.
go back to reference Latchford AR, Sturt NJ, Neale K, et al. A 10-year review of surgery for desmoids disease associated with familial adenomatous polyposis. Br J Surg. 2006;93:1258–64.PubMedCrossRef Latchford AR, Sturt NJ, Neale K, et al. A 10-year review of surgery for desmoids disease associated with familial adenomatous polyposis. Br J Surg. 2006;93:1258–64.PubMedCrossRef
2.
go back to reference Phillips SR, A’Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg. 2004;91:1624–9.PubMedCrossRef Phillips SR, A’Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg. 2004;91:1624–9.PubMedCrossRef
3.
4.
go back to reference Shinagare AB, Ramaiya NH, Jagannathan JP, et al. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008–14.PubMedCrossRef Shinagare AB, Ramaiya NH, Jagannathan JP, et al. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008–14.PubMedCrossRef
5.
go back to reference Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol. 2009;100:563–9.PubMedCrossRef Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol. 2009;100:563–9.PubMedCrossRef
6.
go back to reference Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.PubMedCrossRef Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.PubMedCrossRef
7.
go back to reference Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait and see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–8.PubMedCrossRef Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait and see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–8.PubMedCrossRef
8.
go back to reference Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229–34.PubMedCrossRef Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229–34.PubMedCrossRef
9.
go back to reference Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462–8.PubMedCrossRef Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462–8.PubMedCrossRef
10.
go back to reference Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158–67.PubMed Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17(1):158–67.PubMed
11.
go back to reference Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19(13):4028–35.PubMedCrossRef Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19(13):4028–35.PubMedCrossRef
12.
go back to reference Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036–42.PubMedCentralPubMedCrossRef Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036–42.PubMedCentralPubMedCrossRef
13.
go back to reference Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21(7):1390–7.PubMedCrossRef Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21(7):1390–7.PubMedCrossRef
14.
go back to reference van Broekhoven DL, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–9.PubMedCrossRef van Broekhoven DL, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013;100(9):1214–9.PubMedCrossRef
15.
go back to reference Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45.PubMedCrossRef Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45.PubMedCrossRef
16.
go back to reference Acker JC, Bossen EH, Halperin EC. The management of desmoids tumors. Int J Radiat Oncol Biol Phys. 1993;26:851–8.PubMedCrossRef Acker JC, Bossen EH, Halperin EC. The management of desmoids tumors. Int J Radiat Oncol Biol Phys. 1993;26:851–8.PubMedCrossRef
17.
go back to reference Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer. 1993;72:1637–41.PubMedCrossRef Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer. 1993;72:1637–41.PubMedCrossRef
18.
go back to reference Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159:450–3.PubMedCrossRef Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159:450–3.PubMedCrossRef
19.
go back to reference McKinnon JG, Neifeld JP, Kay S, et al. Management of desmoids tumors. Surg Gynecol Obstet. 1989;169:104–6.PubMed McKinnon JG, Neifeld JP, Kay S, et al. Management of desmoids tumors. Surg Gynecol Obstet. 1989;169:104–6.PubMed
20.
go back to reference Plukker JT, van Oort I, Vermey A, et al. Aggressive fibromatosis(non-familial desmoid tumour): therapeutic problems and the role of adjuvant radiotherapy. Br J Surg. 1995;82:510–4.PubMedCrossRef Plukker JT, van Oort I, Vermey A, et al. Aggressive fibromatosis(non-familial desmoid tumour): therapeutic problems and the role of adjuvant radiotherapy. Br J Surg. 1995;82:510–4.PubMedCrossRef
21.
go back to reference Pritchard DJ, Nascimento AG, Petersen IA. Local control of extraabdominal desmoid tumors. J Bone Joint Surg. 1996;78:848–54.PubMed Pritchard DJ, Nascimento AG, Petersen IA. Local control of extraabdominal desmoid tumors. J Bone Joint Surg. 1996;78:848–54.PubMed
22.
23.
go back to reference Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80(3):787–92.PubMedCrossRef Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80(3):787–92.PubMedCrossRef
24.
go back to reference Micke O, Seegenschmiedt MH. German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882–91.PubMedCrossRef Micke O, Seegenschmiedt MH. German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882–91.PubMedCrossRef
25.
go back to reference Nuyttens JJ, Rust PF, Thomas Jr CR, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88(7):1517–23.PubMedCrossRef Nuyttens JJ, Rust PF, Thomas Jr CR, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88(7):1517–23.PubMedCrossRef
26.
go back to reference Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.PubMedCrossRef Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.PubMedCrossRef
27.
go back to reference de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116(9):2258–65.PubMedCentralPubMed de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116(9):2258–65.PubMedCentralPubMed
28.
go back to reference Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612–20.PubMedCrossRef Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612–20.PubMedCrossRef
29.
go back to reference Nishida Y, Tsukushi S, Shido Y, et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol. 2010;28:e107–9.PubMedCrossRef Nishida Y, Tsukushi S, Shido Y, et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol. 2010;28:e107–9.PubMedCrossRef
30.
go back to reference Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.PubMedCrossRef Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.PubMedCrossRef
31.
go back to reference Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16:4884–91.PubMedCrossRef Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16:4884–91.PubMedCrossRef
32.
go back to reference Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66(9):1369–74.PubMed Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66(9):1369–74.PubMed
34.
go back to reference Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23 Suppl 10:x158–66.PubMedCrossRef Bonvalot S, Desai A, Coppola S, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23 Suppl 10:x158–66.PubMedCrossRef
35.
go back to reference Francis WP, Zippel D, Mack LA, et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol. 2009;16(6):1650–4.PubMedCrossRef Francis WP, Zippel D, Mack LA, et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol. 2009;16(6):1650–4.PubMedCrossRef
36.
go back to reference Fiore M, Rimareix F, Mariani L, et al. Desmoid-typ fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedCrossRef Fiore M, Rimareix F, Mariani L, et al. Desmoid-typ fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedCrossRef
Metadata
Title
Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution
Authors
Wei-gen Zeng
Zhi-xiang Zhou
Jian-wei Liang
Hui-rong Hou
Zheng Wang
Hai-tao Zhou
Xing-mao Zhang
Jun-jie Hu
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2002-1

Other articles of this Issue 8/2014

Tumor Biology 8/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine